985P Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab + rivoceranib in unresectable hepatocellular carcinoma (uHCC)
Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), Laura E. Crotty Alexander(University of Nebraska at Omaha), S.H. Jang(Q Therapeutics (United States)), Chen Yang(Guiyang Medical University), Kexin Shen(Jilin University), Xianzhi Meng(Harbin Medical University), Ming‐Whei Yu(Jen-Ai Hospital), Kara Ryan(Q Therapeutics (United States)), Tao Wei(Liuzhou General Hospital), Meng Zhou(Jiangsu Hengrui Medicine (China)), M. Karkhanis(Q Therapeutics (United States)), James M. Bugni(Q Therapeutics (United States))
Cited by 1
Related Papers
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells
|Blood|2003|1.1k
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569
Epidemiological characteristics and risk factors of hepatocellular carcinoma
|Journal of Gastroenterology and Hepatology|1997|473